CN116115653A - 猴头菇菌丝体活性物质用于制备预防或治疗视网膜病变的组合物的用途 - Google Patents
猴头菇菌丝体活性物质用于制备预防或治疗视网膜病变的组合物的用途 Download PDFInfo
- Publication number
- CN116115653A CN116115653A CN202111561046.7A CN202111561046A CN116115653A CN 116115653 A CN116115653 A CN 116115653A CN 202111561046 A CN202111561046 A CN 202111561046A CN 116115653 A CN116115653 A CN 116115653A
- Authority
- CN
- China
- Prior art keywords
- hericium erinaceus
- mycelium
- erinaceus mycelium
- active substance
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000000588 Hericium erinaceus Species 0.000 title claims abstract description 98
- 235000007328 Hericium erinaceus Nutrition 0.000 title claims abstract description 97
- 239000013543 active substance Substances 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 208000017442 Retinal disease Diseases 0.000 title claims abstract description 13
- 206010038923 Retinopathy Diseases 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 8
- 238000000855 fermentation Methods 0.000 claims abstract description 23
- 230000004151 fermentation Effects 0.000 claims abstract description 23
- 238000012258 culturing Methods 0.000 claims abstract description 17
- 239000001963 growth medium Substances 0.000 claims abstract description 12
- 238000003756 stirring Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003570 air Substances 0.000 claims description 3
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000005273 aeration Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 24
- 206010064930 age-related macular degeneration Diseases 0.000 description 18
- 241000872931 Myoporum sandwicense Species 0.000 description 17
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 17
- 235000015281 sodium iodate Nutrition 0.000 description 17
- 239000011697 sodium iodate Substances 0.000 description 17
- 229940032753 sodium iodate Drugs 0.000 description 17
- 238000000605 extraction Methods 0.000 description 10
- 239000000469 ethanolic extract Substances 0.000 description 9
- 230000002207 retinal effect Effects 0.000 description 9
- 210000001525 retina Anatomy 0.000 description 8
- 239000010410 layer Substances 0.000 description 7
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 7
- 238000010171 animal model Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000012792 core layer Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 206010057430 Retinal injury Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000011122 anti-angiogenic therapy Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000036995 brain health Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Mushroom Cultivation (AREA)
Abstract
本发明提供了一种猴头菇菌丝体活性物质用于制备预防或治疗视网膜病变的组合物的用途。猴头菇菌丝体活性物质可用于制备预防或治疗视网膜病变的组合物。所述猴头菇菌丝体活性物质是由以下列步骤制备而成:(a)取猴头菇菌丝体于平板培养基上,于15‑35℃的温度下培养7‑15天;(b)将步骤(a)培养后的猴头菇菌丝体接种至烧瓶内,于15‑35℃、pH 2‑8的环境培养3‑5天;(c)将步骤(b)培养后的猴头菇菌丝体接种于发酵槽内,于15‑35℃、pH 4.5‑5.5的环境下搅拌培养7‑15天,形成含有猴头菇菌丝体活性物质的猴头菇菌丝体发酵液。
Description
技术领域
本发明关于一种猴头菇菌丝体活性物质的用途,特别是指以猴头菇菌丝体制备用以预防或治疗视网膜病变的组合物。
背景技术
老年性黄斑部病变(Age-related macular degeneration,AMD)是负责视力和色觉的视网膜黄斑部渐进退化性的疾病,主要是由中央视网膜感光接受器死亡所引起。位于感光层和脉络膜之间的视网膜色素上皮(retinal pigment epithelium,RPE)细胞也与早期AMD的发病机制有关。如其名称“老年性”所述,AMD的患病率随着年龄的增长而逐渐增加,成为老年人失明的主要原因。
AMD的发病机制与许多因素有关,如代谢紊乱,免疫,炎症,活性氧物质(reactiveoxygen species;ROS)等。近年的研究显示ROS所造成的氧化压力是AMD的主要致病因子。在过去的几十年中,用来治疗AMD的方法包括:(1)光凝固雷射(laserphotocoagulation)、(2)经瞳热疗雷射(transpupillary thermotherapy TTT)、(3)光动力疗法(photodynamictherapy PDT)、(4)抗血管生成疗法(antiangiogenic therapy)、(5)营养补充疗法、(6)基因治疗、(7)抗氧化剂与(8)合并上述疗法等,但手术疗法具副作用,且术后失明率仍在增加。因此,开发具有较低毒性的新型治疗剂对于AMD的预防或治疗相当重要。
猴头菇Hericium erinaceus(Bull.)Pers是一种珍贵的药膳兼用真菌,主要分布于纬度较高的温带地区。《中国野菜食谱大全》认为其可治消化不良、胃溃疡、胃炎、胃痛、胃胀及神经衰弱等病症,显示猴头菇除美味以外,具有胃部保护功能,可作为食药两用菇。1994年起Kawagishi从猴头菇菌丝体分离纯化得到多种猴头素(A、B、C等),猴头素可刺激老鼠星状细胞,增加神经生长因子分泌量(NGF),而NGF可治疗智力衰退、神经衰弱等疾病,故猴头菇亦被认为可促进神经及大脑健康。然而,目前并无研究指出猴头菇对视网膜病变具有疗效。
发明内容
本发明提供一种猴头菇(Hericium erinaceus)菌丝体活性物质的用途,其是用于制备预防或治疗视网膜病变的组合物。该猴头菇菌丝体活性物质的制备方法包括下列步骤:
(a)取一猴头菇菌丝体于平板培养基上,于15-35℃的温度下培养7-15天;
(b)将步骤(a)培养后的猴头菇菌丝体接种至一烧瓶内,于15-35℃、pH 2-8的环境下培养3-5天;
(c)将步骤(b)培养后的猴头菇菌丝体接种于一发酵槽内,于15-35℃、pH 4.5-5.5的环境下搅拌培养7-15天,形成含有该猴头菇菌丝体活性物质的猴头菇菌丝体发酵液。
一实施例中,制备该猴头菇菌丝体活性物质的步骤还包括步骤(d):将该猴头菇菌丝体发酵液冷冻干燥后磨粉,形成含有该猴头菇菌丝体活性物质的猴头菇菌丝体冻干粉。
一实施例中,制备该猴头菇菌丝体活性物质的步骤还包括步骤(e):将该猴头菇菌丝体冻干粉以一溶剂萃取,形成含有该猴头菇菌丝体活性物质的猴头菇菌丝体萃取液。
一实施例中,制备该猴头菇菌丝体活性物质的步骤还包括步骤(f):将该猴头菇菌丝体萃取液干燥,以获得该猴头菇菌丝体活性物质。
一实施例中,在步骤(e)中的溶剂为乙醇,且该猴头菇菌丝体冻干粉以乙醇重复萃取两次。
一实施例中,步骤(b)的烧瓶培养为震荡培养,且转速为10-250rpm。
一实施例中,该视网膜病变为黄斑部病变。
一实施例中,步骤(c)中该发酵槽进一步通入一气体,该气体包括空气、氧气、二氧化碳、氦气或其组合,该发酵槽的槽压为0.5-2.0kg/cm2且通气速率为0.5-1VVM。
一实施例中,该组合物为医药组合物,且该医药组合物进一步包含药学上可接受的载剂、赋形剂、稀释剂或辅剂。
一实施例中,该组合物为食品添加剂。
一实施例中,该组合物的施用方式为口服、滴剂及栓剂。
为使本发明的上述及其他方面更为清楚,下文特举实施例,并配合所附图式进行说明。
附图说明
图1为各组小鼠的光学断层扫描(Optical Coherence Tomography)图;
图2为图1的视网膜厚度测量结果;
图3中的A为各组小鼠眼睛的苏木精&伊红染色(H&E stain)照片,图3中的B为图3中的A的虚线框放大图;
图4A为图3中的A所示的内核层INL厚度测量结果,图4B为图3中的A所示的外核层ONL厚度测量结果。
具体实施方式
猴头菇菌丝体来源
本发明的实施例所用的猴头菇(Hericium erinaceus)菌种,购置于中国台湾地区‘财团法人食品工业研究所’,寄存编号为BCRC 35669。该菌株可由BCRC的官方网站(https://catalog.bcrc.firdi.org.tw/)直接购得,为公众可轻易取得的菌株。但本发明所述的猴头菇活性物质不限于由此菌种所得。
菌丝体液体培养
将猴头菇菌丝体接种于平板培养基上,于适当温度15-35℃(较佳为25℃)下培养7-15天,刮取菌丝接种于烧瓶内。在15-35℃(较佳为25℃),pH 2-8(较佳为pH 4-7,更佳为pH 5.5),震荡速率100-250rpm的条件下培养3-5天,然后将烧瓶培养物接种于发酵槽培养基(同烧瓶培养基)内,在15-35℃(较佳为25℃),槽压0.5-2.0kg/cm2,pH 4.5-5.5,10-150rpm搅拌速度或不搅拌(air lift)情况,以0.5-1VVM通气速率通入空气,或空气、氧气、二氧化碳、氮气及上述气体的混合物(较佳者为空气),培养时间为7-15天内,即得猴头菇菌丝体发酵液。此发酵液包括菌丝体与澄清液。前述培养条件仅为示例,使用者可视情况调整。
本发明使用的烧瓶培养基、发酵槽培养基配方可如下:
其中该综合性碳氮源可为谷类(如:麦粉类)或豆类(如:黄豆粉、绿豆粉、大豆粉等)。该无机盐类可为硫酸镁、磷酸氢二钾、磷酸二氢钾、硫酸铁等。该糖类可为葡萄糖、果糖、麦芽糖、蔗糖等。特别说明的是,本发明使用的培养基并不限于上述成份或比例,使用者可视实际情况进行调整。
发酵液干燥
此猴头菇菌丝体发酵液可进一步通过干燥步骤制备为冻干粉等其他剂型。干燥方法包括但不限于:喷雾干燥、热风干燥、滚筒干燥、冷冻干燥或其他方式。
冻干粉萃取-乙醇萃取
取猴头菇菌丝体冻干粉加入25倍体积的乙醇进行第1次萃取,利用超声波震荡萃取1小时,取悬浮液进行离心。离心后取上清液,将残渣重复上述萃取步骤,以乙醇进行第二次萃取。第二次萃取获得的上清液与第一次萃取的上清液混合,经减压浓缩,得膏状的猴头菇菌丝体乙醇萃取物,其中包含猴头菇菌丝体活性物质。重复萃取两次的原因是为了获得较高的产率。
上述猴头菇菌丝体发酵液、猴头菇菌丝体冻干粉、猴头菇菌丝体乙醇萃取物皆含有本发明的猴头菇菌丝体活性物质。以下根据上述方法制备猴头菇菌丝体活性物质,并进行生物实验评估其功效。
实施例一:猴头菇菌丝体活性物质制备
菌株:本发明中实施例所用的猴头菇(Hericium erinaceus)菌种购自于财团法人食品工业研究所,寄存编号为BCRC 35669。
平板培养:将菌丝体接种于平板培养基上,培养基为马铃薯糊精培养基(PotatoDextrose Agar,PDA),于25℃下培养7天。
烧瓶培养:刮取平板上的菌丝接种于烧瓶内,用下列培养基配方,在25℃,pH 5.0下,于震荡机上以转速120rpm震荡培养5天;
培养基配方:
发酵槽培养:培养基同上,将烧瓶培养物接种于发酵槽培养基内,在25℃,槽压1.0kg/cm2,pH 5.0下,50rpm搅拌速度,以1.0VVM通气速率通入空气,培养12天,得猴头菇菌丝体发酵液。该猴头菇菌丝体发酵液经冷冻干燥可得猴头菇菌丝体冻干粉。
萃取物制备:将猴头菇菌丝体冻干粉加入为冻干粉25倍重量的95v/v%乙醇进行第一次萃取,接着利用超声波以震荡速率120rpm萃取一小时,取悬浮液进行离心,离心后取上清液。将第一次萃取的残渣重复上述萃取步骤以85v/v%乙醇进行第二次萃取。两次萃取离心得到的上清液混合,经减压浓缩,得膏状的猴头菇菌丝体乙醇萃取物(简称醇萃物)。
结果:20公吨发酵槽培养完毕的猴头菇菌丝体发酵液经冷冻干燥后,可得约320公斤冻干粉,再经二次萃取步骤,可得约20公斤乙醇萃取物。以下生物实验是以猴头菇菌丝体乙醇萃物进行。
实施例二视网膜病变动物模型及相关指标的分析
视网膜病变小鼠动物模型的建立
碘酸钠(Sodium iodate,NaIO3)为一种稳定的氧化剂,已被证明是一种诱导视网膜变性的有效物质。碘酸钠引起的视网膜变性与视网膜色素上皮细胞(RPE)的区域性丧失相关,同时也会出现区域性萎缩的一些形态学特征。已有许多研究利用不同的哺乳动物的物种证实了NaIO3对生物视网膜具有毒性,包括绵羊、兔子、大鼠和小鼠。上述的研究指出在视网膜中,NaIO3主要标靶为RPE细胞,可诱导其死亡,如坏死(necrosis)、细胞凋亡(apoptosis)或细胞自噬(autophagy),其次是脉络膜毛细血管萎缩(choriocapillarisatrophy)和全视网膜变性(panretinal degeneration)。
近年来,研究学者以低剂量NaIO3(15-35mg/kg)来诱导小鼠产生老年性黄斑部病变(Age-related macular degeneration,AMD)模型,发现其与视功能下降以及局部性RPE流失和外部视网膜损伤有关,与干性AMD的共同发病机制极为相似,因此近年来大多以此模型来探讨RPE再生及AMD的预防。
本实施例使用40mg/kg剂量NaIO3诱导小鼠产生AMD,以此动物模型评估猴头菇菌丝体活性物质对于视网膜病变(特别是黄斑部病变)的预防及治疗效果。
实验动物:品系Balb/c雄性小鼠购自中国台湾地区‘实验动物中心’,年龄约6-8周,体重约26.21±1.76g。小鼠饲养于中山医学大学实验动物中心,提供正常洁净饲料及饮水,饲养环境为12小时照光及12小时黑暗的循环光照,温度控制在20±2℃,湿度控制在50±5%。
喂食剂量与实验步骤
本试验共进行21天,试验进行前将小鼠分为4组,每组6只:
(1)空白对照组(Mock):以静脉注射(i.v.)磷酸盐缓冲生理盐水(PBS)100μL后,并以每日口服方式给予PBS 200μL。
(2)负对照组:以静脉注射(i.v.)给予碘酸钠NaIO3 40mg/kg,诱发AMD,并以每日口服方式给予PBS 200μL。
(3)猴头菇乙醇萃取物组(实验组):先以每日口服方式给予实施例一制得的猴头菇乙醇萃取物100mg/kg 14天后,再以静脉注射给予碘酸钠NaIO3 40mg/kg诱发AMD,之后再每日喂食猴头菇乙醇萃取物100mg/kg 7天。
各组小鼠在实验21天后牺牲进行视网膜损伤程度检测及相关指标分析。
视网膜损伤程度检测及相关指标分析
1.眼底影像侦测
使用Phoenix-Micro IV眼底影像侦测系统,可检测光学眼底镜、荧光眼底造影以及视网膜断层扫描仪,并以此依据评估小鼠视网膜组织完整性与平滑度改变。图1为各组小鼠注射碘酸钠第7天后的光学断层扫描(Optical Coherence Tomography)图。
对图1小鼠以视神经为中心,鼻侧与颞侧300μm-600μm的范围(水平线示意处的长度即为300μm)进行6次厚度(垂直线范围)测量后,计算其平均值,可得小鼠的视网膜厚度,其结果见图2。
参照图1的光学断层扫描图,Mock组垂直线标记部分可看出视网膜结构完整。至于仅给予碘酸钠的小鼠组别(NaIO3)的视网膜排列较不规则、松散,且组织间的排序较不平滑、界线较为模糊,有明显视网膜扭曲的情形发生。而通过猴头菇菌丝体萃取物预先处理的小鼠组别(HE)与仅给予碘酸钠的小鼠组别(NaIO3)相比,视网膜排列不规则与模糊的情形明显较少。
图2所示的视网膜厚度测量的结果则显示(其中*号标记表示与单独给予NaIO3组别相比,p<0.05,有显著差异),与空白对照组(Mock)相比,单独给予碘酸钠的小鼠组别(NaIO3)在接受碘酸钠注射7天后,视网膜厚度有明显变薄情形。而通过猴头菇菌丝体萃取物(HE)预先处理的小鼠组别与单独给予碘酸钠的小鼠组别(NaIO3)相比,虽然厚度仍有变薄,但仍有显著回升。
据此,可得知本发明实施例的猴头菇菌丝体萃取物可减缓碘酸钠NaIO3所诱导的小鼠视网膜扭曲与变薄,进而改善AMD的情形。
2.组织病理分析(H&E stainine)
将各组小鼠于注射碘酸钠第7天后进行牺牲采血,眼睛做组织切片后,以苏木精和伊红染色,区别RPE的结构与型态,其照片如图3中的A所示。图3中的B为图3中的A的虚线框放大图,用以观察内核层(Inner nuclear layer,INL)与外核层(Outer nuclear layer,ONL)厚度,以及观察发炎细胞的数量。
INL及ONL层厚度测试皆是以视神经为中心,在其鼻侧与颞侧300μm-600μm进行6次厚度(图3中的B所示的线段与INL、ONL标记)测量后,计算其平均值,其结果分别列于图4A与图4B,其中*号标记表示与单独给予NaIO3组别相比,p<0.05,有显著差异。
与空白对照组(Mock)相比,单独给予碘酸钠的小鼠组别(NaIO3)在接受碘酸钠注射7天后,视网膜ONL与INL层厚度皆有变薄的情形。而通过猴头菇菌丝体萃取物(HE)预先处理的小鼠组别与单独给予碘酸钠的小鼠组别(NaIO3)相比,可显著减缓碘酸钠诱导的小鼠视网膜ONL与INL层厚度变薄。
据此,可得知本发明实施例的猴头菇菌丝体萃取物可减缓碘酸钠(NaIO3)诱导的小鼠视网膜内核层与外核层变薄,进而改善AMD的情形。
实施例三组合物制备
本实施例的猴头菇菌丝体活性物质若应用于医药用途,则以下组合物1的态样作为例示性实例。
组合物1:取实施例一的猴头菇菌丝体活性物质的冻干粉或水萃物(20wt%),与作为润滑剂的硬脂酸镁(8wt%)、作为防腐剂的二氧化硅(7wt%)充分混合,并溶于纯水(65wt%)中,存放于4℃备用。前述wt%是指各成分占组合物总重的比例。
不过,虽然实施例二中的猴头菇菌丝体活性物质是以口服方式喂食小鼠,但实际应用上亦可采用如滴剂、栓剂等其他方式。
本实施例的猴头菇菌丝体活性物质若以液体剂型应用于食品用途,则以下组合物2的态样作为例示性实例。
组合物2:取实施例一的猴头菇菌丝体活性物质的冻干粉或水萃物(20wt%),与作为防腐剂的苯乙醇(8wt%)、作为稀释剂的甘油(7wt%)、作为稀释剂的蔗糖(10wt%)充分混合,并溶于纯水(55wt%)中,存放于4℃备用。前述wt%是指各成分占组合物总重的比例。
Claims (11)
1.一种猴头菇菌丝体活性物质用于制备预防或治疗视网膜病变的组合物的用途,其中该猴头菇菌丝体活性物质的制备方法包括下列步骤:
(a)取一猴头菇菌丝体于平板培养基上,于15-35℃的温度下培养7-15天;
(b)将步骤(a)培养后的猴头菇菌丝体接种至一烧瓶内,于15-35℃、pH 2-8的环境培养3-5天;
(c)将步骤(b)培养后的猴头菇菌丝体接种于一发酵槽内,于15-35℃、pH 4.5-5.5的环境下搅拌培养7-15天,形成含有该猴头菇菌丝体活性物质的猴头菇菌丝体发酵液。
2.如权利要求1所述的用途,其中制备该猴头菇菌丝体活性物质的步骤还包括步骤(d):将该猴头菇菌丝体发酵液冷冻干燥后磨粉,形成含有该猴头菇菌丝体活性物质的猴头菇菌丝体冻干粉。
3.如权利要求2所述的用途,其中制备该猴头菇菌丝体活性物质的步骤还包括步骤(e):将该猴头菇菌丝体冻干粉以一溶剂萃取,形成含有该猴头菇菌丝体活性物质的猴头菇菌丝体萃取液。
4.如权利要求3所述的用途,其中制备该猴头菇菌丝体活性物质的步骤还包括步骤(f):将该猴头菇菌丝体萃取液干燥,以获得该猴头菇菌丝体活性物质。
5.如权利要求3或4所述的用途,其中在步骤(e)中,该溶剂为乙醇,且该猴头菇菌丝体冻干粉以乙醇重复萃取两次。
6.如权利要求1所述的用途,其中步骤(b)的烧瓶培养为震荡培养,且转速为10-250rpm。
7.如权利要求1所述的用途,其中该视网膜病变为黄斑部病变。
8.如权利要求1所述的用途,其中步骤(c)中该发酵槽进一步通入一气体,该气体包括空气、氧气、二氧化碳、氦气或其组合,该发酵槽的槽压为0.5-2.0kg/cm2且通气速率为0.5-1VVM。
9.如权利要求1所述的用途,其中该组合物为医药组合物,该医药组合物进一步包含药学上可接受的载剂、赋形剂、稀释剂或辅剂。
10.如权利要求1所述的用途,其中该组合物为食品添加剂。
11.如权利要求1所述的用途,其中该组合物的施用方式包括口服、滴剂及栓剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110142437 | 2021-11-15 | ||
TW110142437A TWI798936B (zh) | 2021-11-15 | 2021-11-15 | 猴頭菇菌絲體活性物質用於預防或治療視網膜病變之用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116115653A true CN116115653A (zh) | 2023-05-16 |
CN116115653B CN116115653B (zh) | 2024-05-10 |
Family
ID=86310642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111561046.7A Active CN116115653B (zh) | 2021-11-15 | 2021-12-15 | 猴头菇菌丝体活性物质用于制备预防或治疗视网膜病变的组合物的用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116115653B (zh) |
TW (1) | TWI798936B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106860485A (zh) * | 2015-12-14 | 2017-06-20 | 葡萄王生技股份有限公司 | 治疗失智症的活性物质、含其的组合物及其制备方法 |
-
2021
- 2021-11-15 TW TW110142437A patent/TWI798936B/zh active
- 2021-12-15 CN CN202111561046.7A patent/CN116115653B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106860485A (zh) * | 2015-12-14 | 2017-06-20 | 葡萄王生技股份有限公司 | 治疗失智症的活性物质、含其的组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
KYOKO OHNO-MATSUI: "Parallel findings in age-related macular degeneration and Alzheimer’s disease", 《PROGRESS IN RETINAL AND EYE RESEARCH》, pages 217 - 238 * |
Also Published As
Publication number | Publication date |
---|---|
CN116115653B (zh) | 2024-05-10 |
TWI798936B (zh) | 2023-04-11 |
TW202321434A (zh) | 2023-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10865377B2 (en) | Cordyceps cicadae mycelium active substances, preparation method, pharmaceutical composition and application thereof | |
CN106265768B (zh) | 蝉花活性物质、其制备方法、包含其的医药组合物及其用途 | |
CN107982285B (zh) | 蝉花活性物质及其用于降低眼压的用途 | |
Haden | Elective localization in the eye of bacteria from infected teeth | |
US10342833B2 (en) | Active substances of Cordyceps cicadae and its uses in preventing, delaying or treating cataracts | |
KR20220012381A (ko) | 아커만시아 뮤시니필라 균주 또는 이의 배양물을 유효성분으로 함유하는 노화방지용 조성물 | |
CN116115653B (zh) | 猴头菇菌丝体活性物质用于制备预防或治疗视网膜病变的组合物的用途 | |
US10849918B2 (en) | Composition for optic nerve protection | |
US20200061134A1 (en) | Method for preventing, postponing or treating changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment | |
TWI788083B (zh) | 蟬花菌絲體活性物質用於治療黃斑部病變之用途 | |
CN109200066A (zh) | 蝉花活性物质及其用于预防、延缓或治疗白内障的用途 | |
CN106309508B (zh) | 樟芝菌丝体活性物质及其制法、含其的医药组合物及用途 | |
CN113185581B (zh) | 一种环十肽化合物及其在治疗新生儿缺氧缺血性脑病中的应用 | |
TWI811009B (zh) | 蟬花活性物質用於改善視力之用途 | |
CN111544440A (zh) | 地奥司明及组合物在制备抗肥胖的产品方面中的应用 | |
CN114191444B (zh) | Lc-a在制备治疗和预防增殖性糖尿病性视网膜病变药物中的应用 | |
CN114767685B (zh) | 四氢叶酸在抑菌或者预防或治疗眼部疾病中的用途 | |
WO2022240165A1 (ko) | 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물 | |
TWI749362B (zh) | 蟬花子實體萃取物、其製造方法及其用於降低眼壓之用途 | |
CN1631427A (zh) | 一种抗菌、抗病毒、抗炎作用的滴眼液及其制备方法 | |
JP2004083555A (ja) | アナフィラキシー疾患治療剤、アナフィラキシー疾患症状改善のための健康食品およびその製造方法 | |
CN108888621A (zh) | 左旋千金藤啶碱在制备抑制近视药物上的应用及其使用方法 | |
JP2004000242A (ja) | 酵母およびそれを用いた発酵生成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |